HIV-1 Infection
Conditions
Brief summary
This study was done to compare the safety and efficacy of three combination treatments for Kaposi's Sarcoma (KS) and AIDS: 1. Etoposide (ET) plus co-formulated Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) (ET+ART), 2. Bleomycin and Vincristine (BV) plus co-formulated EFV/FTC/TDF (BV+ART), 3. Paclitaxel (PTX) plus co-formulated EFV/FTC/TDF (PTX+ART).
Detailed description
The study consisted of four steps. Study duration was up to 240 weeks. At the study Step 1 entry, participants were randomized with equal probability to each of the three regimens (ET+ART, BV+ART, PTX+ART). The original target sample size was 706. Randomization was stratified by: 1. Screening CD4 lymphocyte cell count (\<100, \>=100 cells/mm³), and 2. Country. For participants who had an initial Independent Endpoint Review Committee (IERC) confirmed KS response and subsequent IERC-confirmed KS progression, and who, in the opinion of the investigator and with concurrence of the protocol Clinical Management Committee (CMC), could potentially have benefitted from another course of the same chemotherapy utilized in Step 1, entered Step 2. (Please see details on Step 2 eligibility.) In Step 3, participants were randomized with equal probability to one of the two chemotherapy arms not utilized in Step 1. (Please see details on Step 3 eligibility.) In Step 4, participants were assigned to the remaining study-provided chemotherapy not given in Step 1, Step 2 or Step 3. (Please see details on Step 4 eligibility.) Step 1 visits occurred at screening, entry and weeks 3, 6, 9, 12, 15, 18, 21,24, 27, 30, 33, 36, 39, 42, 45, 48, 60, 72, 84 and 96 from study entry. Visits for Steps 2, 3 and 4 were scheduled at entry and weeks 3, 6, 9, 12, 15, 18, 21,24, 27, 30, 33, 36, 39, 42, 45, 48, 60, 72, 84 and 96 from the corresponding step entry date. Key evaluations included targeted physical examination, clinical assessment, KS examination, hematology, chemistry, pregnancy testing (for women of reproductive potential), and pulse oximetry for participants on BV+ART. CD4 count and HIV viral load were obtained every 12 weeks. Assessment of peripheral neuropathy was done at screening, weeks 9 and 21, and for those on BV+ART or PTX+ART, additionally at weeks 3, 6, 15 and 18. KS tumor punch biopsy, serum, plasma and peripheral blood mononuclear cells (PBMCs) were obtained and stored for use in future analyses. Participants also completed ET and ART adherence evaluations and quality of life questionnaires. Enrollment to ET+ART and initiation of ET+ART in subsequent steps were discontinued in March 2016, based on the recommendation of the Data and Safety Monitoring Board (DSMB) due to ET+ART being less effective than PTX+ART. No safety concerns were identified. ET+ART participants in Step 1 or Step 2, in discussion with the local investigator and in consultation with the protocol CMC, could discontinue ET and enter Step 3. ET+ART participants in Step 3 could discontinue ET and start the remaining chemotherapy regimen in Step 4 in discussion with the local investigator and in consultation with the protocol CMC. Unless otherwise indicated, comparison between ET+ART and PTX+ART was based on the March 2016 data. The study remained open to enrollment and the remaining participants were randomized at Step 1 entry between BV+ART and PTX+ART. The target total sample size was revised to 446. The DSMB recommended stopping the study in March 2018 due to BV+ART being inferior to PTX+ART. No safety concerns were identified. Study accrual was stopped. Eligible Step 1 PTX+ART participants entered Step 2 to receive PTX+ART; Step 1 and Step 2 BV+ART participants eligible to receive PTX+ART moved to Step 3 to receive PTX+ART. Otherwise, participants permanently transitioned to local care upon arrangement of appropriate oncology and ART, and then went off study. Participants who received ET while on study were followed for 144 weeks after beginning the last cycle of ET. Comparison between BV+ART and PTX+ART was based on the March 2018 data.
Interventions
DRUGEtoposide (ET)
Beginning on day one of the chemotherapy cycle, ET was given orally in a dose of 50 mg twice daily for 7 consecutive days for the first cycle. If there was no Grade \>= 2 toxicity attributable to ET after the first cycle, the dose was escalated to 150 mg daily for 7 days in divided doses of 100 mg/50 mg for the second cycle. After the second cycle, if there was no Grade \>= 2 toxicity attributable to ET, the dose was escalated to 100 mg twice daily for 7 days for the third and subsequent cycles. Treatment with ET was continued for six cycles at the maximum dose achieved or until toxicity requiring discontinuation of study chemotherapy, or the site investigator, after consulting with the protocol CMC, had determined that alternative therapy is required, whichever occurs first.
DRUGBleomycin and Vincristine (BV)
BV was administered on day one of each chemotherapy cycle. Vincristine sulfate was administered at a dose of 2 mg (fixed dose) in a volume of 2 mL over 1 minute into the sidearm of a rapidly flowing intravenous infusion every 3 weeks. The vincristine infusion was followed by bleomycin as detailed below. Bleomycin sulfate was administered at a dose of 15 units/m\^2 over 10 minutes every 3 weeks. Treatment with BV was continued for six cycles, or until toxicity requiring discontinuation of study chemotherapy, or the site investigator, after consulting with the protocol CMC, had determined that alternative therapy is required, whichever occurs first.
DRUGPaclitaxel (PTX)
Paclitaxel was administered by IV infusion in 200 mL, 250 mL, or 500 mL of 5% dextrose or 0.9%Sodium Chloride for injection at a dose of 100 mg/m\^2 body surface area (BSA) every 3 weeks.
DRUGCo-formulated Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF)
The following ART regimens were used: 1. EFV/FTC/TDF (Atripla) 200 mg/300 mg/600 mg orally once daily at bedtime or 2. FTC/TDF 200 mg/300 mg (Truvada) orally once daily at bedtime plus EFV (Stocrin) 600 mg orally once daily at bedtime or 3. FTC/TDF 200 mg/300 mg (Truvada) orally once daily plus nevirapine (NVP) 200 mg orally twice daily or 4. FTC/TDF 200 mg/300 mg (Truvada) orally once daily plus PI/r at standard dosing or 5. FTC/TDF 200 mg/300 mg (Truvada) orally once daily plus integrase inhibitor at standard dosing
Sponsors
National Institute of Allergy and Infectious Diseases (NIAID)
National Cancer Institute (NCI)
National Institute of Dental and Craniofacial Research (NIDCR)
AIDS Malignancy Consortium
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
for Step 1: 1. HIV-1 infection 2. Biopsy diagnostic of KS at any time prior to study entry. 3. Current KS stage T1 using ACTG criteria. 4. A minimum of five indicator KS cutaneous marker lesions (or if fewer than five marker lesions are available, the total surface area of the marker lesion(s) must be \>=700 mm\^2) plus an additional two lesions greater or equal to 4x4 mm that are accessible for punch biopsy. 5. CD4+ lymphocyte cell count obtained within 28 days prior to study entry at a DAIDS-approved laboratory. 6. Certain laboratory values, as defined in the protocol, obtained within 14 days prior to study entry. 7. Female study volunteers of reproductive potential must have a negative serum or urine pregnancy test with a sensitivity of 15-25 mIU/mL performed within 48 hours before initiating the protocol-specified medications. 8. All participants must agree not to participate in a conception process (active attempt to become pregnant or to impregnate, donate sperm, in vitro fertilization). 9. If participating in sexual activity that could lead to pregnancy, participant must agree that two reliable forms of contraceptives will be used simultaneously while receiving protocol-specified medications, and for 12 weeks after stopping the medications. Study volunteers who are not of reproductive potential (women who have been post-menopausal for at least 24 consecutive months or have undergone hysterectomy and/or bilateral oophorectomy or men who have documented azoospermia) are eligible without requiring the use of contraceptives. 10. Ability to swallow oral medications and adequate venous access. 11. Karnofsky performance status \>= 60 within 28 days prior to entry. 12. Ability and willingness of participant or legal guardian/representative to provide informed consent.
Exclusion criteria
for Step 1: 1. Current chronic, acute, or recurrent serious infections for which the participant has not completed at least 14 days of therapy prior to study entry and/or is not clinically stable. 2. Serious illness requiring systemic treatment and/or hospitalization within 14 days prior to entry. 3. Current or history of known pulmonary fibrosis, chronic obstructive pulmonary disease (COPD), emphysema, bronchiectasis, or diffuse or significant local radiographic interstitial infiltrates on chest x-ray (CXR) or computed axial tomography (CT) scan. 4. Oxygen saturation less than 90% and/or exercise desaturation greater than 4% within 14 days prior to study enrollment. 5. Grade \>=3 peripheral neuropathy (PN) at entry. 6. Breastfeeding. 7. Receipt of ART for more than 42 days immediately prior to entry. 8. Prior or current systemic or locally administered chemotherapy. 9. Prior or current radiation therapy. 10. Prior or current immunotherapy, e.g., interferon alfa. 11. Corticosteroid use at doses above those given as replacement therapy for adrenal insufficiency within the last 30 days prior to study entry. 12. Any immunomodulator, HIV vaccine, live attenuated vaccines, or other investigational therapy or investigational vaccine within 30 days prior to study entry. 13. Known allergy/sensitivity or any hypersensitivity to components of study drugs or their formulation. 14. Active drug or alcohol use or dependence that would interfere with adherence to study requirements. 15. Current or anticipated receipt of any of the prohibited medications listed in section 5.5.2 of the protocol. 16. In the opinion of the investigator, any psychological or social condition, or addictive disorder that would preclude compliance with the protocol. Inclusion Criteria for Step 2: 1. IERC-confirmed complete response (CR) or partial response (PR) to the chemotherapy regimen used in Step 1. 2. IERC-confirmed KS progression at least 12 weeks after the last dose of Step 1 chemotherapy. 3. Fewer than 72 weeks after Step 1 entry 4. Certain laboratory values, as defined in the protocol, obtained within 14 days prior to Step 2 entry. 5. For females of reproductive potential or females not of reproductive potential who do not have required documentation, negative serum or urine pregnancy test with a sensitivity of 15-25 mIU/mL within 7 days prior to Step 2 entry. 6. Karnofsky performance status \>=50 within 28 days prior to Step 2 7. All participants must agree not to participate in a conception process (active attempt to become pregnant or to impregnate, donate sperm, in vitro fertilization).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Cumulative Rate of Progression-Free Survival by Week 48 for ET+ART vs. PTX+ART | From study entry to week 48 | Progression-free survival (PFS) by week 48 is defined as a lack of the following events: (a) Independent Endpoint Review Committee (IERC)-confirmed KS progression, (b) death, (c) entry into an additional step, or (d) loss to follow-up, prior to week 48. PFS rate was estimated by the Kaplan-Meier survival probability at week 48. Time to event was computed as the number of weeks from study entry to the first among these events. For participants who did not have any of the events, event time was censored at the week of last contact with the participant. Follow-up time beyond 48 was censored at week 48. Overall KS outcome status (complete response, partial response, stable, disease progression) was based on comparing follow-up to study entry or best KS response with respect to clinical assessment of KS cutaneous lesions (count, character and marker lesion area), oral KS, visceral KS and tumor-associated edema and as described in the publications (Krown et al 1989, Cianfrocca et al 2002). |
| Cumulative Rate of Progression-Free Survival by Week 48 for BV+ART vs. PTX+ART | From study entry to week 48 | Progression-free survival (PFS) by week 48 is defined as a lack of the following events: (a) Independent Endpoint Review Committee (IERC)-confirmed KS progression, (b) death, (c) entry into an additional step, or (d) loss to follow-up, prior to week 48. PFS rate was estimated by the Kaplan-Meier survival probability at week 48. Time to event was computed as the number of weeks from study entry to the first among these events. For participants who did not have any of the events, event time was censored at the week of last contact with the participant. Follow-up time beyond 48 was censored at week 48. Overall KS outcome status (complete response, partial response, stable, disease progression) was based on comparing follow-up to study entry or best KS response with respect to clinical assessment of KS cutaneous lesions (count, character and marker lesion area), oral KS, visceral KS and tumor-associated edema and as described in the publications (Krown et al 1989, Cianfrocca et al 2002). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Salivary KSHV | Baseline, weeks 60, 120, 180, 240 | Funding for oral KS objectives including data and sample collection was withdrawn during the study conduct. |
| Changes in CD4+ Lymphocyte Cell Count for BV+ART vs. PTX+ART | Baseline, weeks 12, 24, 48 | Baseline CD4 lymphocyte cell count is the mean of screening and Step 1 entry CD4 values. Absolute change in CD4+ lymphocyte cell count was calculated as value at a given visit minus the baseline CD4 lymphocyte cell count. |
| Self-reported Adherence to ART Therapy | At Weeks 6, 12, 18, 30 and 48 | ART adherence is based on participant's recall of the number of missed ART doses for the past month. Perfect adherence is defined as having zero missed ART doses. |
| Presence of Oral KS | From study entry to week 240 | Funding for oral KS objectives including data and sample collection was withdrawn during the study conduct. |
| Number of Participants With IERC-Confirmed KS Disease Progression, Dose-Limiting Toxicity, Death, AIDS-Defining Events, Virologic Failure and Objective Response in Step 2 | From Step 2 study entry to Step 2 discontinuation, up to 144 weeks | IERC-confirmed KS progression refers to KS disease progression confirmed by the IERC based on comparing follow-up KS response to study entry or best KS response with respect to clinical assessment of KS cutaneous lesions (count, character and marker lesion area), oral KS, visceral KS and tumor-associated edema and as described in the publications (Krown et al 1989, Cianfrocca et al 2002). AIDS-defining events refer to non-KS AIDS-defining diagnosis (WHO Stage 4 (2007), plus microsporidiosis, cyclospora gastroenteritis, Chagas disease and visceral leishmaniasis). Virologic failure is defined as two successive measurements of plasma HIV-1 RNA \>=1000 copies/mL at week 12 to week 24 or RNA \>=400 copies/mL at week 24 or later. Objective response refers to complete response or partial response as best overall KS response. Results are presented by Step 2 treatment arm. |
| Number of Participants With IERC-Confirmed KS Disease Progression, Dose-Limiting Toxicity, Death, AIDS-Defining Events, Virologic Failure and Objective Response in Step 3 | From Step 3 study entry to Step 3 discontinuation, up to 144 weeks | IERC-confirmed KS progression refers to KS disease progression confirmed by the IERC based on comparing follow-up KS response to study entry or best KS response with respect to clinical assessment of KS cutaneous lesions (count, character and marker lesion area), oral KS, visceral KS and tumor-associated edema and as described in the publications (Krown et al 1989, Cianfrocca et al 2002). AIDS-defining events refer to non-KS AIDS-defining diagnosis (WHO Stage 4 (2007), plus microsporidiosis, cyclospora gastroenteritis, Chagas disease and visceral leishmaniasis). Virologic failure is defined as two successive measurements of plasma HIV-1 RNA \>=1000 copies/mL at week 12 to week 24 or RNA \>=400 copies/mL at week 24 or later. Objective response refers to complete response or partial response as best overall KS response. Results are presented by Step 3 treatment arm. |
| Number of Participants With IERC-Confirmed KS Disease Progression, Dose-Limiting Toxicity, Death, AIDS-Defining Events, Virologic Failure and Objective Response in Step 4 | From Step 4 study entry to Step 4 discontinuation, up to 96 weeks | IERC-confirmed KS progression refers to KS disease progression confirmed by the IERC based on comparing follow-up KS response to study entry or best KS response with respect to clinical assessment of KS cutaneous lesions (count, character and marker lesion area), oral KS, visceral KS and tumor-associated edema and as described in the publications (Krown et al 1989, Cianfrocca et al 2002). AIDS-defining events refer to non-KS AIDS-defining diagnosis (WHO Stage 4 (2007), plus microsporidiosis, cyclospora gastroenteritis, Chagas disease and visceral leishmaniasis). Virologic failure is defined as two successive measurements of plasma HIV-1 RNA \>=1000 copies/mL at week 12 to week 24 or RNA \>=400 copies/mL at week 24 or later. Objective response refers to complete response or partial response as best overall KS response. Results are presented by Step 4 treatment arm. |
| Cumulative Rate of Death by Week 48 for ET+ART vs. PTX+ART | From study entry to week 48 | The Kaplan-Meier estimate of the cumulative rate of death by week 48. Time to death was computed as the number of weeks from study entry to date of death. For participants who did have the event, time to death was censored at the week of last contact with the participant. Time to death above 48 were censored at week 48. |
| Cumulative Rate of Death by Week 48 for BV+ART vs. PTX+ART | From study entry to week 48 | The Kaplan-Meier estimate of the cumulative rate of death by week 48. Time to death was computed as the number of weeks from study entry to the death date. For participants who did have the event, time to death was censored at the week of last contact with the participant. Time to death above 48 were censored at week 48. |
| Cumulative Rate of IERC-confirmed KS Progression by Week 48 for ET+ART vs. PTX+ART | From study entry to week 48 | The Kaplan-Meier estimate of the cumulative rate of IERC-confirmed KS progression by week 48. IERC-confirmed KS progression was defined as KS disease progression confirmed by the IERC based on comparing follow-up KS response to study entry or best KS response with respect to clinical assessment of KS cutaneous lesions (count, character and marker lesion area), oral KS, visceral KS and tumor-associated edema and as described in the publications (Krown et al 1989, Cianfrocca et al 2002). |
| Cumulative Rate of IERC-confirmed KS Progression by Week 48 for BV+ART vs. PTX+ART | From study entry to week 48 | The Kaplan-Meier estimate of the cumulative rate of IERC-confirmed KS progression by week 48. IERC-confirmed KS progression was defined as KS disease progression confirmed by the IERC based on comparing follow-up KS response to study entry or best KS response with respect to clinical assessment of KS cutaneous lesions (count, character and marker lesion area), oral KS, visceral KS and tumor-associated edema and as described in the publications (Krown et al 1989, Cianfrocca et al 2002). |
| Cumulative Rate of AIDS-defining Event by Week 48 for ET+ART vs. PTX+ART | From study entry to week 48 | The Kaplan-Meier estimate of the cumulative rate of AIDS-defining events by week 48. AIDS-defining events refer to non-KS AIDS-defining diagnosis (WHO Stage 4 (2007), plus microsporidiosis, cyclospora gastroenteritis, Chagas disease and visceral leishmaniasis). Time to event was computed as the number of weeks from study entry to the first AIDS-defining event. For participants who did not have any of the events, event time was censored at the week of last contact with the participant. Follow-up time beyond 48 was censored at week 48. |
| Cumulative Rate of AIDS-defining Event by Week 48 for BV+ART vs. PTX+ART | From study entry to week 48 | The Kaplan-Meier estimate of the cumulative rate of AIDS-defining events by week 48. AIDS-defining events refer to non-KS AIDS-defining diagnosis (WHO Stage 4 (2007), plus microsporidiosis, cyclospora gastroenteritis, Chagas disease and visceral leishmaniasis). Time to event was computed as the number of weeks from study entry to the first AIDS-defining event. For participants who did not have any of the events, event time was censored at the week of last contact with the participant. Follow-up time beyond 48 was censored at week 48. |
| Cumulative Rate of HIV-1 RNA Virologic Failure by Week 48 for ET+ART vs. PTX+ART | From study entry to week 48 | Virologic failure is defined as two successive measurements of plasma HIV-1 RNA \>=1000 copies/mL at week 12 to week 24 or RNA \>=400 copies/mL at week 24 or later. |
| Cumulative Rate of HIV-1 RNA Virologic Failure by Week 48 for BV+ART vs. PTX+ART | From study entry to week 48 | Virologic failure is defined as two successive measurements of plasma HIV-1 RNA \>=1000 copies/mL at week 12 to week 24 or RNA \>=400 copies/mL at week 24 or later. |
| Number of Participants With Kaposi's Sarcoma-Immune Reconstitution Inflammatory Syndrome (KS-IRIS) for ET+ART vs. PTX+ART | From study entry to week 12 | KS-IRIS is defined as any IERC-confirmed KS-progression that occurs within 12 weeks of ART-initiation that is associated with an increase in CD4 cell count of at least 50 cells/mm\^3 above the study entry value and/or a decrease in the HIV-1 RNA level by at least 0.5 log below the study entry value prior to or at the time of documented KS progression. |
| Number of Participants With Kaposi's Sarcoma-Immune Reconstitution Inflammatory Syndrome (KS-IRIS) for BV+ART vs. PTX+ART | From study entry to week 12 | KS-IRIS is defined as any IERC-confirmed KS-progression that occurs within 12 weeks of ART-initiation that is associated with an increase in CD4 cell count of at least 50 cells/mm\^3 above the study entry value and/or a decrease in the HIV-1 RNA level by at least 0.5 log below the study entry value prior to or at the time of documented KS progression. |
| Cumulative Rate of KS Progression, Death, or AIDS Defining Event by Week 48 for ET+ART vs. PTX+ART | From study entry to week 48 | The Kaplan-Meier estimate of the cumulative rate of KS progression, death, or AIDS defining event by week 48 |
| Cumulative Rate of KS Progression, Death, or AIDS Defining Event by Week 48 for BV+ART vs. PTX+ART | From study entry to week 48 | The Kaplan-Meier estimate of the cumulative rate of KS progression, death, or AIDS defining event by week 48 |
| Cumulative Rate of KS Progression, Death, AIDS Defining Event, or Virologic Failure by Week 48 for ET+ART vs. PTX+ART | From study entry to week 48 | The Kaplan-Meier estimate of the cumulative rate of KS progression, death, AIDS defining event, or virologic failure by week 48 |
| Cumulative Rate of KS Progression, Death, AIDS Defining Event, or Virologic Failure by Week 48 for BV+ART vs. PTX+ART | From study entry to week 48 | The Kaplan-Meier estimate of the cumulative rate of KS progression, death, AIDS defining event, or virologic failure by week 48 |
| Cumulative Rate of KS Progression, Death, AIDS Defining Event, Virologic Failure, or KS-IRIS by Week 48 for ET+ART vs. PTX+ART | From study entry to week 48 | The Kaplan-Meier estimate of the cumulative rate of KS progression, death, AIDS defining event, virologic failure, or KS-IRIS. |
| Cumulative Rate of KS Progression, Death, AIDS Defining Event, Virologic Failure, or KS-IRIS by Week 48 for BV+ART vs. PTX+ART | From study entry to week 48 | The Kaplan-Meier estimate of the cumulative rate of KS progression, death, AIDS defining event, virologic failure, or KS-IRIS. |
| Cumulative Rate of Change in KS Treatment by Week 48 for ET+ART vs. PTX+ART | From study entry to week 48 | The Kaplan-Meier estimate of the cumulative rate of change in KS treatment by week 48. Change in KS treatment was defined as stopping Step 1 randomized chemotherapy and initiating a different chemotherapy. |
| Cumulative Rate of Change in KS Treatment by Week 48 for BV+ART vs. PTX+ART | From study entry to week 48 | The Kaplan-Meier estimate of the cumulative rate of change in KS treatment by week 48. Change in KS treatment was defined as stopping Step 1 randomized chemotherapy and initiating a different chemotherapy. |
| Cumulative Rate of Death for ET+ART vs. PTX+ART | From study entry to week 240 | The Kaplan-Meier estimate of the cumulative rate of death. Time to death was computed as the number of weeks between study entry and date of death. For participants who did not have the event, time to death was censored at the week of last contact with the participant or at the participant's off study week, whichever is later. |
| Cumulative Rate of Death for BV+ART vs PTX+ART | From study entry to week 240 | The Kaplan-Meier estimate of the cumulative rate of death. Time to death was computed as the number of weeks between study entry and date of death. For participants who did not have the event, time to death was censored at the week of last contact with the participant or at the participant's off study week, whichever is later. |
| Time to IERC-confirmed KS Progression or Death for ET+ART vs. PTX+ART | From study entry to week 240 | Time to IERC-confirmed KS progression or death was computed as the number of weeks between study entry and the earlier between date of IERC-confirmed KS progression or date of death. For participants who did not have the event, event time was censored at the week of last contact with the participant or the participant's off study week, whichever is later. The 25-th percentile and hazard ratio are presented. |
| Time to IERC-confirmed KS Progression or Death for BV+ART vs. PTX+ART | From study entry to week 240 | Time to IERC-confirmed KS progression or death was computed as the number of weeks between study entry and the earlier between date of IERC-confirmed KS progression or date of death. For participants who did not have the event, event time was censored at the week of last contact with the participant or at the participant's off study week, whichever is later.The 25-th percentile and hazard ratio are presented. |
| Number of Participants With Objective Response for ET+ART vs. PTX+ART | From study entry up to week 144 | The number of participants with objective response (complete response or partial response) as best overall KS response in Step 1. Overall KS response status (complete response, partial response, stable, disease progression) was based on comparing follow-up KS response to study entry or best KS response with respect to clinical assessment of KS cutaneous lesions (count, character and marker lesion area), oral KS, visceral KS and tumor-associated edema and as described in the publications (Krown et al 1989, Cianfrocca et al 2002). |
| Number of Participants With Objective Response for BV+ART vs. PTX+ART | From study entry up to week 144 | The number of participants with objective response (complete response or partial response) as best overall KS response in Step 1. Overall KS response status (complete response, partial response, stable, disease progression) was based on comparing follow-up KS response to study entry or best KS response with respect to clinical assessment of KS cutaneous lesions (count, character and marker lesion area), oral KS, visceral KS and tumor-associated edema and as described in the publications (Krown et al 1989, Cianfrocca et al 2002). |
| Duration of Objective Response for ET+ART vs. PTX+ART | From study entry up to week 144 | Duration of objective response is the number of weeks from first complete or partial response to the earliest among progression, death or off study week. The 25th percentile duration is presented. |
| Duration of Objective Response for BV+ART vs. PTX+ART | From study entry up to week 144 | Duration of objective response is the number of weeks from first complete or partial response to the earliest among progression, death or off study week. The 25th percentile duration is presented. |
| Number of Participants With Symptomatic Peripheral Neuropathy (SPN) | Screening, Weeks 3, 6, 9, 12, 15, 18, 21. Assessment of SPN for ET+ART was only done at screening, weeks 9 and 21. | SPN consists of three assessments: (1) pain, aching or burning in feet, legs, (2) pins and needles in feet, legs, and (3) numbness (lack of feeling) in feet, legs. SPN is graded on a severity scale from 0 (not present), 1 (mild) to 10 (severe). Presence of SPN is defined as having grade \>=1 in at least one of the three assessments. |
| Number of Participants With Peripheral Neuropathy (PN) | Screening, Weeks 3, 6, 9, 12, 15, 18, 21. Assessment of PN for ET+ART was only done at screening, weeks 9 and 21. | Presence of PN is defined as having all of the following results: presence of symptomatic PN, abnormal perception of vibrations, and absent or hypoactive deep tendon reflexes. |
| Number of Participants With Treatment-related Toxicities and Adverse Events (AEs) | From study entry to week 240 | Adverse events classified by the site personnel as possibly, probably or definitely related to ART or chemotherapy. |
| Changes in CD4+ Lymphocyte Cell Count for ET+ART vs. PTX+ART | Baseline, weeks 12, 24, 48 | Baseline CD4 lymphocyte cell count is the mean of screening and Step 1 entry CD4 values. Absolute change in CD4+ lymphocyte cell count was calculated as value at a given visit minus the baseline CD4 lymphocyte cell count. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Cellular and Humoral Markers of Immune Function and Activation | Baseline, weeks 60, 120, 180, 240 | The protocol did not distinguish between outcome measures essential to the primary publication and those of lesser importance and priority which are not the focus of the study but intended for subsequent publications of exploratory analyses, conditional on primary results and additional funding. This outcome measure was listed under secondary outcome measures in the study protocol but was intended for an exploratory analysis to evaluate the relationship between response of KS to therapy and development of KS-IRIS with cellular and humoral markers of immune function and activation. The laboratory assays for this outcome measure have not been completed. |
| Plasma KS-associated Herpesvirus (KSHV) | Baseline, weeks 60, 120, 180, 240 | The protocol did not distinguish between outcome measures essential to the primary publication and those of lesser importance and priority which are not the focus of the study but intended for subsequent publications of exploratory analyses, conditional on primary results and additional funding. This outcome measure was listed under secondary outcome measures in the study protocol but was intended for an exploratory analysis to investigate the relationship between plasma and PBMC KSHV viral load. The laboratory assays for this outcome measure have not been completed. |
| Peripheral Blood Mononuclear Cell (PBMC) KSHV | Baseline, weeks 60, 120, 180, 240 | The protocol did not distinguish between outcome measures essential to the primary publication and those of lesser importance and priority which are not the focus of the study but intended for subsequent publications of exploratory analyses, conditional on primary results and additional funding. This outcome measure was listed under secondary outcome measures in the study protocol but was intended for an exploratory analysis to investigate the relationship between plasma and PBMC KSHV viral load. The laboratory assays for this outcome measure have not been completed. |
| Quality of Life Measures | Baseline, weeks 60, 120, 180, 240 | The protocol did not distinguish between outcome measures essential to the primary publication and those of lesser importance and priority which are not the focus of the study but intended for subsequent publications of exploratory analyses, conditional on primary results and additional funding. This outcome measure was listed under secondary outcome measures in the study protocol but was intended for an exploratory analysis to compare measures of quality of life in ET+ART, BV+ART and PTX+ART. |
| Immunohistochemical Evaluations of Viral and Cellular Gene Expression | Baseline, 24-48 hours after 2nd chemo-therapy cycle begins | The protocol did not distinguish between outcome measures essential to the primary publication and those of lesser importance and priority which are not the focus of the study but intended for subsequent publications of exploratory analyses, conditional on primary results and additional funding. This outcome measure was listed under secondary outcome measures in the study protocol but was intended for an exploratory analysis to evaluate the relationship between response of KS to therapy and development of KS-IRIS with immunohistochemical markers of viral and cellular gene expression in KS tumors. The laboratory assays for this outcome measure have not been completed. |
| RNA Levels for KSHV Genes | Baseline, weeks 60, 120, 180, 240 | The protocol did not distinguish between outcome measures essential to the primary publication and those of lesser importance and priority which are not the focus of the study but intended for subsequent publications of exploratory analyses, conditional on primary results and additional funding. This outcome measure was listed under secondary outcome measures in the study protocol but was intended for an exploratory analysis to evaluate the relationship between response of KS to therapy and development of KS-IRIS with RNA levels for KSHV genes in tumor biopsies. The laboratory assays for this outcome measure have not been completed. |
Countries
Brazil, Kenya, Malawi, South Africa, Uganda, Zimbabwe
Participant flow
Recruitment details
Participants were recruited from October 2013 to March 2018 at 11 sites from Africa and South America (Brazil).
Participants by arm
| Arm | Count |
|---|---|
| BV+ART Bleomycin and Vincristine plus ART (co-formulated Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate) | 132 |
| ET+ART Etoposide plus ART (co-formulated Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate) | 59 |
| PTX+ART Paclitaxel plus ART (co-formulated Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate) | 138 |
| Total | 329 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 |
|---|---|---|---|---|
| Overall Study | Death | 37 | 18 | 25 |
| Overall Study | Enrollment Violation | 0 | 1 | 0 |
| Overall Study | Never started chemotherapy | 3 | 0 | 1 |
| Overall Study | Not able to get to clinic | 2 | 0 | 2 |
| Overall Study | Not willing to adhere to requirements | 0 | 2 | 3 |
| Overall Study | Severe debilitation, unable to continue | 0 | 0 | 1 |
| Overall Study | Site is closing | 4 | 9 | 7 |
| Overall Study | Unable to contact participant/parent | 1 | 1 | 1 |
| Overall Study | Withdrew consent | 0 | 3 | 1 |
Baseline characteristics
| Characteristic | PTX+ART | ET+ART | BV+ART | Total |
|---|---|---|---|---|
| Age, Continuous | 35 years | 35 years | 35 years | 35 years |
| CD4 Cell Count | 231 cells/mm^3 | 216 cells/mm^3 | 232 cells/mm^3 | 229 cells/mm^3 |
| CD4 Cell Count, categorized <100 cells/mm^3 | 30 Participants | 14 Participants | 26 Participants | 70 Participants |
| CD4 Cell Count, categorized >=100 cells/mm^3 | 108 Participants | 45 Participants | 106 Participants | 259 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 7 Participants | 2 Participants | 5 Participants | 14 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 131 Participants | 57 Participants | 127 Participants | 315 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| HIV-1 RNA, categorized >=10,000 copies/mL | 70 Participants | 43 Participants | 77 Participants | 190 Participants |
| HIV-1 RNA, categorized 1000 to <10,000 copies/mL | 20 Participants | 10 Participants | 12 Participants | 42 Participants |
| HIV-1 RNA, categorized <400 copies/mL | 38 Participants | 4 Participants | 29 Participants | 71 Participants |
| HIV-1 RNA, categorized 400 to <1,000 copies/mL | 10 Participants | 2 Participants | 14 Participants | 26 Participants |
| HIV-1 RNA, continuous | 4.0 Log10 copies/mL | 4.9 Log10 copies/mL | 4.6 Log10 copies/mL | 4.4 Log10 copies/mL |
| Karnofsky Performance Score 100 | 1 Participants | 0 Participants | 0 Participants | 1 Participants |
| Karnofsky Performance Score 60 | 1 Participants | 1 Participants | 1 Participants | 3 Participants |
| Karnofsky Performance Score 70 | 14 Participants | 7 Participants | 11 Participants | 32 Participants |
| Karnofsky Performance Score 80 | 47 Participants | 19 Participants | 41 Participants | 107 Participants |
| Karnofsky Performance Score 90 | 75 Participants | 32 Participants | 79 Participants | 186 Participants |
| Number of Cutaneous KS Lesions <=50 lesions | 51 Participants | 21 Participants | 32 Participants | 104 Participants |
| Number of Cutaneous KS Lesions >50 lesions | 87 Participants | 38 Participants | 100 Participants | 225 Participants |
| Presence of Lower Limb Edema | 56 Participants | 24 Participants | 71 Participants | 151 Participants |
| Presence of Lower Limb Edema in Both Limbs | 22 Participants | 11 Participants | 39 Participants | 72 Participants |
| Presence of Oral Cavity KS Lesions | 80 Participants | 36 Participants | 90 Participants | 206 Participants |
| Presence of Visceral KS | 32 Participants | 20 Participants | 36 Participants | 88 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 136 Participants | 58 Participants | 130 Participants | 324 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 2 Participants | 1 Participants | 2 Participants | 5 Participants |
| Region of Enrollment Brazil | 7 participants | 2 participants | 5 participants | 14 participants |
| Region of Enrollment Kenya | 29 participants | 2 participants | 27 participants | 58 participants |
| Region of Enrollment Malawi | 56 participants | 27 participants | 54 participants | 137 participants |
| Region of Enrollment South Africa | 8 participants | 0 participants | 7 participants | 15 participants |
| Region of Enrollment Uganda | 9 participants | 10 participants | 7 participants | 26 participants |
| Region of Enrollment Zimbabwe | 29 participants | 18 participants | 32 participants | 79 participants |
| Sex: Female, Male Female | 31 Participants | 14 Participants | 31 Participants | 76 Participants |
| Sex: Female, Male Male | 107 Participants | 45 Participants | 101 Participants | 253 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 37 / 132 | 33 / 59 | 55 / 138 |
| other Total, other adverse events | 130 / 132 | 58 / 59 | 133 / 138 |
| serious Total, serious adverse events | 54 / 132 | 33 / 59 | 55 / 138 |
Outcome results
Primary
Cumulative Rate of Progression-Free Survival by Week 48 for BV+ART vs. PTX+ART
Progression-free survival (PFS) by week 48 is defined as a lack of the following events: (a) Independent Endpoint Review Committee (IERC)-confirmed KS progression, (b) death, (c) entry into an additional step, or (d) loss to follow-up, prior to week 48. PFS rate was estimated by the Kaplan-Meier survival probability at week 48. Time to event was computed as the number of weeks from study entry to the first among these events. For participants who did not have any of the events, event time was censored at the week of last contact with the participant. Follow-up time beyond 48 was censored at week 48. Overall KS outcome status (complete response, partial response, stable, disease progression) was based on comparing follow-up to study entry or best KS response with respect to clinical assessment of KS cutaneous lesions (count, character and marker lesion area), oral KS, visceral KS and tumor-associated edema and as described in the publications (Krown et al 1989, Cianfrocca et al 2002).
Time frame: From study entry to week 48
Population: All eligible participants who initiated study chemotherapy with available data as of March 2018.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| ET+ART | Cumulative Rate of Progression-Free Survival by Week 48 for BV+ART vs. PTX+ART | 44.1 Cumulative events per 100 persons |
| PTX+ART | Cumulative Rate of Progression-Free Survival by Week 48 for BV+ART vs. PTX+ART | 64.2 Cumulative events per 100 persons |
Comparison: Treatment comparison was made using the difference (BV+ART - PTX+ART) in the stratified Kaplan-Meier estimate for the week 48 PFS rate with 95% two-sided confidence interval.95% CI: [-32.3, -7.4]
Comparison: Treatment comparison was made using the difference (BV+ART - PTX+ART) in the stratified Kaplan-Meier estimate for the week 48 cumulative PFS rate with 95% two-sided confidence interval.95% CI: [-32.2, -7.9]
Primary
Cumulative Rate of Progression-Free Survival by Week 48 for ET+ART vs. PTX+ART
Progression-free survival (PFS) by week 48 is defined as a lack of the following events: (a) Independent Endpoint Review Committee (IERC)-confirmed KS progression, (b) death, (c) entry into an additional step, or (d) loss to follow-up, prior to week 48. PFS rate was estimated by the Kaplan-Meier survival probability at week 48. Time to event was computed as the number of weeks from study entry to the first among these events. For participants who did not have any of the events, event time was censored at the week of last contact with the participant. Follow-up time beyond 48 was censored at week 48. Overall KS outcome status (complete response, partial response, stable, disease progression) was based on comparing follow-up to study entry or best KS response with respect to clinical assessment of KS cutaneous lesions (count, character and marker lesion area), oral KS, visceral KS and tumor-associated edema and as described in the publications (Krown et al 1989, Cianfrocca et al 2002).
Time frame: From study entry to week 48
Population: All eligible participants who initiated study chemotherapy with available data as of March 2016.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| ET+ART | Cumulative Rate of Progression-Free Survival by Week 48 for ET+ART vs. PTX+ART | 19.7 Cumulative events per 100 persons |
| PTX+ART | Cumulative Rate of Progression-Free Survival by Week 48 for ET+ART vs. PTX+ART | 49.8 Cumulative events per 100 persons |
Comparison: Treatment comparison was made using the difference (ET+ART - PTX+ART) in the stratified Kaplan-Meier estimate for the week 48 PFS rate with 95% two-sided confidence interval.95% CI: [-52.3, -8.3]
Secondary
Changes in CD4+ Lymphocyte Cell Count for BV+ART vs. PTX+ART
Baseline CD4 lymphocyte cell count is the mean of screening and Step 1 entry CD4 values. Absolute change in CD4+ lymphocyte cell count was calculated as value at a given visit minus the baseline CD4 lymphocyte cell count.
Time frame: Baseline, weeks 12, 24, 48
Population: All eligible participants who initiated study chemotherapy with available data as of March 2018.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| ET+ART | Changes in CD4+ Lymphocyte Cell Count for BV+ART vs. PTX+ART | Week 12 CD4 change | 21 cells/mm^3 |
| ET+ART | Changes in CD4+ Lymphocyte Cell Count for BV+ART vs. PTX+ART | Week 24 CD4 change | 43 cells/mm^3 |
| ET+ART | Changes in CD4+ Lymphocyte Cell Count for BV+ART vs. PTX+ART | Week 48 CD4 change | 112 cells/mm^3 |
| PTX+ART | Changes in CD4+ Lymphocyte Cell Count for BV+ART vs. PTX+ART | Week 48 CD4 change | 105 cells/mm^3 |
| PTX+ART | Changes in CD4+ Lymphocyte Cell Count for BV+ART vs. PTX+ART | Week 12 CD4 change | 37 cells/mm^3 |
| PTX+ART | Changes in CD4+ Lymphocyte Cell Count for BV+ART vs. PTX+ART | Week 24 CD4 change | 65 cells/mm^3 |
Secondary
Changes in CD4+ Lymphocyte Cell Count for ET+ART vs. PTX+ART
Baseline CD4 lymphocyte cell count is the mean of screening and Step 1 entry CD4 values. Absolute change in CD4+ lymphocyte cell count was calculated as value at a given visit minus the baseline CD4 lymphocyte cell count.
Time frame: Baseline, weeks 12, 24, 48
Population: All eligible participants who initiated study chemotherapy with available data as of March 2016.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| ET+ART | Changes in CD4+ Lymphocyte Cell Count for ET+ART vs. PTX+ART | Week 12 CD4 change | 37 cells/mm^3 |
| ET+ART | Changes in CD4+ Lymphocyte Cell Count for ET+ART vs. PTX+ART | Week 24 CD4 change | 106 cells/mm^3 |
| ET+ART | Changes in CD4+ Lymphocyte Cell Count for ET+ART vs. PTX+ART | Week 48 CD4 change | 69 cells/mm^3 |
| PTX+ART | Changes in CD4+ Lymphocyte Cell Count for ET+ART vs. PTX+ART | Week 12 CD4 change | 47 cells/mm^3 |
| PTX+ART | Changes in CD4+ Lymphocyte Cell Count for ET+ART vs. PTX+ART | Week 24 CD4 change | 95 cells/mm^3 |
| PTX+ART | Changes in CD4+ Lymphocyte Cell Count for ET+ART vs. PTX+ART | Week 48 CD4 change | 157 cells/mm^3 |
Secondary
Cumulative Rate of AIDS-defining Event by Week 48 for BV+ART vs. PTX+ART
The Kaplan-Meier estimate of the cumulative rate of AIDS-defining events by week 48. AIDS-defining events refer to non-KS AIDS-defining diagnosis (WHO Stage 4 (2007), plus microsporidiosis, cyclospora gastroenteritis, Chagas disease and visceral leishmaniasis). Time to event was computed as the number of weeks from study entry to the first AIDS-defining event. For participants who did not have any of the events, event time was censored at the week of last contact with the participant. Follow-up time beyond 48 was censored at week 48.
Time frame: From study entry to week 48
Population: All eligible participants who initiated study chemotherapy with available data as of March 2018.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| ET+ART | Cumulative Rate of AIDS-defining Event by Week 48 for BV+ART vs. PTX+ART | 17.9 Cumulative events per 100 persons |
| PTX+ART | Cumulative Rate of AIDS-defining Event by Week 48 for BV+ART vs. PTX+ART | 19.6 Cumulative events per 100 persons |
Comparison: Treatment comparison was made using the difference (BV+ART - PTX+ART) in the stratified Kaplan-Meier estimate for the week 48 cumulative rate of AIDS-defining events with 95% two-sided confidence interval.95% CI: [-13.3, 6.6]
Secondary
Cumulative Rate of AIDS-defining Event by Week 48 for ET+ART vs. PTX+ART
The Kaplan-Meier estimate of the cumulative rate of AIDS-defining events by week 48. AIDS-defining events refer to non-KS AIDS-defining diagnosis (WHO Stage 4 (2007), plus microsporidiosis, cyclospora gastroenteritis, Chagas disease and visceral leishmaniasis). Time to event was computed as the number of weeks from study entry to the first AIDS-defining event. For participants who did not have any of the events, event time was censored at the week of last contact with the participant. Follow-up time beyond 48 was censored at week 48.
Time frame: From study entry to week 48
Population: All eligible participants who initiated study chemotherapy with available data as of March 2016.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| ET+ART | Cumulative Rate of AIDS-defining Event by Week 48 for ET+ART vs. PTX+ART | 15.2 Cumulative events per 100 persons |
| PTX+ART | Cumulative Rate of AIDS-defining Event by Week 48 for ET+ART vs. PTX+ART | 28.6 Cumulative events per 100 persons |
Comparison: Treatment comparison was made using the difference (ET+ART - PTX+ART) in the stratified Kaplan-Meier estimate for the week 48 cumulative rate of AIDS-defining events with 95% two-sided confidence interval.95% CI: [-34.4, 4.3]
Secondary
Cumulative Rate of Change in KS Treatment by Week 48 for BV+ART vs. PTX+ART
The Kaplan-Meier estimate of the cumulative rate of change in KS treatment by week 48. Change in KS treatment was defined as stopping Step 1 randomized chemotherapy and initiating a different chemotherapy.
Time frame: From study entry to week 48
Population: All eligible participants who initiated study chemotherapy with available data as of March 2018.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| ET+ART | Cumulative Rate of Change in KS Treatment by Week 48 for BV+ART vs. PTX+ART | 32.5 Cumulative events per 100 persons |
| PTX+ART | Cumulative Rate of Change in KS Treatment by Week 48 for BV+ART vs. PTX+ART | 18.9 Cumulative events per 100 persons |
Comparison: Treatment comparison was made using the difference (BV+ART - PTX+ART) in the stratified Kaplan-Meier estimate for the week 48 cumulative rate of change in KS treatment.95% CI: [-0.4, 22.7]
Secondary
Cumulative Rate of Change in KS Treatment by Week 48 for ET+ART vs. PTX+ART
The Kaplan-Meier estimate of the cumulative rate of change in KS treatment by week 48. Change in KS treatment was defined as stopping Step 1 randomized chemotherapy and initiating a different chemotherapy.
Time frame: From study entry to week 48
Population: All eligible participants who initiated study chemotherapy with available data as of March 2016.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| ET+ART | Cumulative Rate of Change in KS Treatment by Week 48 for ET+ART vs. PTX+ART | 59.5 Cumulative events per 100 persons |
| PTX+ART | Cumulative Rate of Change in KS Treatment by Week 48 for ET+ART vs. PTX+ART | 26.0 Cumulative events per 100 persons |
Comparison: Treatment comparison was made using the difference (ET+ART - PTX+ART) in the stratified Kaplan-Meier estimate for the week 48 cumulative rate of change in KS treatment.95% CI: [13.6, 61.4]
Secondary
Cumulative Rate of Death by Week 48 for BV+ART vs. PTX+ART
The Kaplan-Meier estimate of the cumulative rate of death by week 48. Time to death was computed as the number of weeks from study entry to the death date. For participants who did have the event, time to death was censored at the week of last contact with the participant. Time to death above 48 were censored at week 48.
Time frame: From study entry to week 48
Population: All eligible participants who initiated study chemotherapy with available data as of March 2018.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| ET+ART | Cumulative Rate of Death by Week 48 for BV+ART vs. PTX+ART | 18.5 Cumulative events per 100 persons |
| PTX+ART | Cumulative Rate of Death by Week 48 for BV+ART vs. PTX+ART | 10.3 Cumulative events per 100 persons |
Comparison: Treatment comparison was made using the difference (BV+ART - PTX+ART) in the stratified Kaplan-Meier estimate for the week 48 cumulative rate of death with 95% two-sided confidence interval.95% CI: [-0.4, 17.2]
Secondary
Cumulative Rate of Death by Week 48 for ET+ART vs. PTX+ART
The Kaplan-Meier estimate of the cumulative rate of death by week 48. Time to death was computed as the number of weeks from study entry to date of death. For participants who did have the event, time to death was censored at the week of last contact with the participant. Time to death above 48 were censored at week 48.
Time frame: From study entry to week 48
Population: All eligible participants who initiated study chemotherapy with available data as of March 2016.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| ET+ART | Cumulative Rate of Death by Week 48 for ET+ART vs. PTX+ART | 25.6 Cumulative events per 100 persons |
| PTX+ART | Cumulative Rate of Death by Week 48 for ET+ART vs. PTX+ART | 10.7 Cumulative events per 100 persons |
Comparison: Treatment comparison was made using the difference (ET+ART - PTX+ART) in the stratified Kaplan-Meier estimate for the week 48 cumulative rate of death with 95% two-sided confidence interval.95% CI: [-1.9, 31.4]
Secondary
Cumulative Rate of Death for BV+ART vs PTX+ART
The Kaplan-Meier estimate of the cumulative rate of death. Time to death was computed as the number of weeks between study entry and date of death. For participants who did not have the event, time to death was censored at the week of last contact with the participant or at the participant's off study week, whichever is later.
Time frame: From study entry to week 240
Population: All eligible participants who initiated study chemotherapy with available data as of March 2018.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| ET+ART | Cumulative Rate of Death for BV+ART vs PTX+ART | 18.5 Cumulative events per 100 persons |
| PTX+ART | Cumulative Rate of Death for BV+ART vs PTX+ART | 10.3 Cumulative events per 100 persons |
Comparison: Treatment comparison was made using the difference (BV+ART - PTX+ART) in the stratified Kaplan-Meier estimate for the cumulative rate of death with 95% two-sided confidence interval.95% CI: [-0.4, 17.2]
Secondary
Cumulative Rate of Death for ET+ART vs. PTX+ART
The Kaplan-Meier estimate of the cumulative rate of death. Time to death was computed as the number of weeks between study entry and date of death. For participants who did not have the event, time to death was censored at the week of last contact with the participant or at the participant's off study week, whichever is later.
Time frame: From study entry to week 240
Population: All eligible participants who initiated study chemotherapy with available data as of March 2016.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| ET+ART | Cumulative Rate of Death for ET+ART vs. PTX+ART | 25.6 Cumulative events per 100 persons |
| PTX+ART | Cumulative Rate of Death for ET+ART vs. PTX+ART | 10.7 Cumulative events per 100 persons |
Comparison: Treatment comparison was made using the difference (ET+ART - PTX+ART) in the stratified Kaplan-Meier estimate for the cumulative rate of death with 95% two-sided confidence interval.95% CI: [-1.9, 31.4]
Secondary
Cumulative Rate of HIV-1 RNA Virologic Failure by Week 48 for BV+ART vs. PTX+ART
Virologic failure is defined as two successive measurements of plasma HIV-1 RNA \>=1000 copies/mL at week 12 to week 24 or RNA \>=400 copies/mL at week 24 or later.
Time frame: From study entry to week 48
Population: All eligible participants who initiated study chemotherapy with available data as of March 2018.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| ET+ART | Cumulative Rate of HIV-1 RNA Virologic Failure by Week 48 for BV+ART vs. PTX+ART | 7.4 Cumulative events per 100 persons |
| PTX+ART | Cumulative Rate of HIV-1 RNA Virologic Failure by Week 48 for BV+ART vs. PTX+ART | 1.8 Cumulative events per 100 persons |
Comparison: Treatment comparison was made using the difference (BV+ART - PTX+ART) in the stratified Kaplan-Meier estimate for the week 48 cumulative rate of HIV-1 RNA virologic failure with 95% two-sided confidence interval.95% CI: [-0.1, 11]
Secondary
Cumulative Rate of HIV-1 RNA Virologic Failure by Week 48 for ET+ART vs. PTX+ART
Virologic failure is defined as two successive measurements of plasma HIV-1 RNA \>=1000 copies/mL at week 12 to week 24 or RNA \>=400 copies/mL at week 24 or later.
Time frame: From study entry to week 48
Population: All eligible participants who initiated study chemotherapy with available data as of March 2016.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| ET+ART | Cumulative Rate of HIV-1 RNA Virologic Failure by Week 48 for ET+ART vs. PTX+ART | 7.8 Cumulative events per 100 persons |
| PTX+ART | Cumulative Rate of HIV-1 RNA Virologic Failure by Week 48 for ET+ART vs. PTX+ART | 0.0 Cumulative events per 100 persons |
Comparison: Treatment comparison was made using the difference (ET+ART - PTX+ART) in the stratified Kaplan-Meier estimate for the week 48 cumulative rate of HIV-1 RNA virologic failure with 95% two-sided confidence interval.95% CI: [-1.9, 10.6]
Secondary
Cumulative Rate of IERC-confirmed KS Progression by Week 48 for BV+ART vs. PTX+ART
The Kaplan-Meier estimate of the cumulative rate of IERC-confirmed KS progression by week 48. IERC-confirmed KS progression was defined as KS disease progression confirmed by the IERC based on comparing follow-up KS response to study entry or best KS response with respect to clinical assessment of KS cutaneous lesions (count, character and marker lesion area), oral KS, visceral KS and tumor-associated edema and as described in the publications (Krown et al 1989, Cianfrocca et al 2002).
Time frame: From study entry to week 48
Population: All eligible participants who initiated study chemotherapy with available data as of March 2018.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| ET+ART | Cumulative Rate of IERC-confirmed KS Progression by Week 48 for BV+ART vs. PTX+ART | 43.9 Cumulative events per 100 persons |
| PTX+ART | Cumulative Rate of IERC-confirmed KS Progression by Week 48 for BV+ART vs. PTX+ART | 25.7 Cumulative events per 100 persons |
Comparison: Treatment comparison was made using the difference (BV+ART - PTX+ART) in the stratified Kaplan-Meier estimate for the week 48 cumulative rate of IERC-confirmed KS progression with 95% two-sided confidence interval.95% CI: [3.7, 28.8]
Secondary
Cumulative Rate of IERC-confirmed KS Progression by Week 48 for ET+ART vs. PTX+ART
The Kaplan-Meier estimate of the cumulative rate of IERC-confirmed KS progression by week 48. IERC-confirmed KS progression was defined as KS disease progression confirmed by the IERC based on comparing follow-up KS response to study entry or best KS response with respect to clinical assessment of KS cutaneous lesions (count, character and marker lesion area), oral KS, visceral KS and tumor-associated edema and as described in the publications (Krown et al 1989, Cianfrocca et al 2002).
Time frame: From study entry to week 48
Population: All eligible participants who initiated study chemotherapy with available data as of March 2016.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| ET+ART | Cumulative Rate of IERC-confirmed KS Progression by Week 48 for ET+ART vs. PTX+ART | 69.8 Cumulative events per 100 persons |
| PTX+ART | Cumulative Rate of IERC-confirmed KS Progression by Week 48 for ET+ART vs. PTX+ART | 41.2 Cumulative events per 100 persons |
Secondary
Cumulative Rate of KS Progression, Death, AIDS Defining Event, or Virologic Failure by Week 48 for BV+ART vs. PTX+ART
The Kaplan-Meier estimate of the cumulative rate of KS progression, death, AIDS defining event, or virologic failure by week 48
Time frame: From study entry to week 48
Population: All eligible participants who initiated study chemotherapy with available data as of March 2018.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| ET+ART | Cumulative Rate of KS Progression, Death, AIDS Defining Event, or Virologic Failure by Week 48 for BV+ART vs. PTX+ART | 60.9 Cumulative events per 100 persons |
| PTX+ART | Cumulative Rate of KS Progression, Death, AIDS Defining Event, or Virologic Failure by Week 48 for BV+ART vs. PTX+ART | 42.0 Cumulative events per 100 persons |
Comparison: Treatment comparison was made using the difference (BV+ART - PTX+ART) in the stratified Kaplan-Meier estimate for the week 48 cumulative rate of KS progression, death, AIDS defining event, or virologic failure.95% CI: [6.3, 31.3]
Secondary
Cumulative Rate of KS Progression, Death, AIDS Defining Event, or Virologic Failure by Week 48 for ET+ART vs. PTX+ART
The Kaplan-Meier estimate of the cumulative rate of KS progression, death, AIDS defining event, or virologic failure by week 48
Time frame: From study entry to week 48
Population: All eligible participants who initiated study chemotherapy with available data as of March 2016.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| ET+ART | Cumulative Rate of KS Progression, Death, AIDS Defining Event, or Virologic Failure by Week 48 for ET+ART vs. PTX+ART | 77.5 Cumulative events per 100 persons |
| PTX+ART | Cumulative Rate of KS Progression, Death, AIDS Defining Event, or Virologic Failure by Week 48 for ET+ART vs. PTX+ART | 54.6 Cumulative events per 100 persons |
Comparison: Treatment comparison was made using the difference (ET+ART - PTX+ART) in the stratified Kaplan-Meier estimate for the week 48 cumulative rate of KS progression, death, AIDS defining event, or virologic failure.95% CI: [0.9, 47.4]
Secondary
Cumulative Rate of KS Progression, Death, AIDS Defining Event, Virologic Failure, or KS-IRIS by Week 48 for BV+ART vs. PTX+ART
The Kaplan-Meier estimate of the cumulative rate of KS progression, death, AIDS defining event, virologic failure, or KS-IRIS.
Time frame: From study entry to week 48
Population: All eligible participants who initiated study chemotherapy with available data as of March 2018.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| ET+ART | Cumulative Rate of KS Progression, Death, AIDS Defining Event, Virologic Failure, or KS-IRIS by Week 48 for BV+ART vs. PTX+ART | 54.5 Cumulative events per 100 persons |
| PTX+ART | Cumulative Rate of KS Progression, Death, AIDS Defining Event, Virologic Failure, or KS-IRIS by Week 48 for BV+ART vs. PTX+ART | 36.2 Cumulative events per 100 persons |
Comparison: Treatment comparison was made using the difference (BV+ART - PTX+ART) in the stratified Kaplan-Meier estimate for the week 48 cumulative rate of KS progression, death, AIDS defining event, virologic failure, or KS-IRIS.95% CI: [6.2, 29.3]
Secondary
Cumulative Rate of KS Progression, Death, AIDS Defining Event, Virologic Failure, or KS-IRIS by Week 48 for ET+ART vs. PTX+ART
The Kaplan-Meier estimate of the cumulative rate of KS progression, death, AIDS defining event, virologic failure, or KS-IRIS.
Time frame: From study entry to week 48
Population: All eligible participants who initiated study chemotherapy with available data as of March 2016.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| ET+ART | Cumulative Rate of KS Progression, Death, AIDS Defining Event, Virologic Failure, or KS-IRIS by Week 48 for ET+ART vs. PTX+ART | 57.6 Cumulative events per 100 persons |
| PTX+ART | Cumulative Rate of KS Progression, Death, AIDS Defining Event, Virologic Failure, or KS-IRIS by Week 48 for ET+ART vs. PTX+ART | 33.9 Cumulative events per 100 persons |
Comparison: Treatment comparison was made using the difference (ET+ART - PTX+ART) in the stratified Kaplan-Meier estimate for the week 48 cumulative rate of KS progression, death, AIDS defining event, virologic failure, or KS-IRIS.95% CI: [0.9, 47.4]
Secondary
Cumulative Rate of KS Progression, Death, or AIDS Defining Event by Week 48 for BV+ART vs. PTX+ART
The Kaplan-Meier estimate of the cumulative rate of KS progression, death, or AIDS defining event by week 48
Time frame: From study entry to week 48
Population: All eligible participants who initiated study chemotherapy with available data as of March 2018.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| ET+ART | Cumulative Rate of KS Progression, Death, or AIDS Defining Event by Week 48 for BV+ART vs. PTX+ART | 56.7 Cumulative events per 100 persons |
| PTX+ART | Cumulative Rate of KS Progression, Death, or AIDS Defining Event by Week 48 for BV+ART vs. PTX+ART | 42.1 Cumulative events per 100 persons |
Comparison: Treatment comparison was made using the difference (BV+ART - PTX+ART) in the stratified Kaplan-Meier estimate for the week 48 cumulative rate of KS progression, death, or AIDS defining event.95% CI: [1.8, 27]
Secondary
Cumulative Rate of KS Progression, Death, or AIDS Defining Event by Week 48 for ET+ART vs. PTX+ART
The Kaplan-Meier estimate of the cumulative rate of KS progression, death, or AIDS defining event by week 48
Time frame: From study entry to week 48
Population: All eligible participants who initiated study chemotherapy with available data as of March 2016.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| ET+ART | Cumulative Rate of KS Progression, Death, or AIDS Defining Event by Week 48 for ET+ART vs. PTX+ART | 72.4 Cumulative events per 100 persons |
| PTX+ART | Cumulative Rate of KS Progression, Death, or AIDS Defining Event by Week 48 for ET+ART vs. PTX+ART | 54.6 Cumulative events per 100 persons |
Comparison: Treatment comparison was made using the difference (ET+ART - PTX+ART) in the stratified Kaplan-Meier estimate for the week 48 cumulative rate of KS progression, death, or AIDS defining event.95% CI: [-4.1, 43]
Secondary
Duration of Objective Response for BV+ART vs. PTX+ART
Duration of objective response is the number of weeks from first complete or partial response to the earliest among progression, death or off study week. The 25th percentile duration is presented.
Time frame: From study entry up to week 144
Population: All eligible participants who initiated study chemotherapy with complete of partial KS response in Step 1 as of March 2018.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| ET+ART | Duration of Objective Response for BV+ART vs. PTX+ART | 21.0 weeks |
| PTX+ART | Duration of Objective Response for BV+ART vs. PTX+ART | 45.7 weeks |
Secondary
Duration of Objective Response for ET+ART vs. PTX+ART
Duration of objective response is the number of weeks from first complete or partial response to the earliest among progression, death or off study week. The 25th percentile duration is presented.
Time frame: From study entry up to week 144
Population: All eligible participants who initiated study chemotherapy with complete of partial KS response in Step 1 as of March 2016.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| ET+ART | Duration of Objective Response for ET+ART vs. PTX+ART | 10.1 weeks |
| PTX+ART | Duration of Objective Response for ET+ART vs. PTX+ART | 19.9 weeks |
Secondary
Number of Participants With IERC-Confirmed KS Disease Progression, Dose-Limiting Toxicity, Death, AIDS-Defining Events, Virologic Failure and Objective Response in Step 2
IERC-confirmed KS progression refers to KS disease progression confirmed by the IERC based on comparing follow-up KS response to study entry or best KS response with respect to clinical assessment of KS cutaneous lesions (count, character and marker lesion area), oral KS, visceral KS and tumor-associated edema and as described in the publications (Krown et al 1989, Cianfrocca et al 2002). AIDS-defining events refer to non-KS AIDS-defining diagnosis (WHO Stage 4 (2007), plus microsporidiosis, cyclospora gastroenteritis, Chagas disease and visceral leishmaniasis). Virologic failure is defined as two successive measurements of plasma HIV-1 RNA \>=1000 copies/mL at week 12 to week 24 or RNA \>=400 copies/mL at week 24 or later. Objective response refers to complete response or partial response as best overall KS response. Results are presented by Step 2 treatment arm.
Time frame: From Step 2 study entry to Step 2 discontinuation, up to 144 weeks
Population: All eligible participants who entered Step 2 with available data as of March 2018.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| ET+ART | Number of Participants With IERC-Confirmed KS Disease Progression, Dose-Limiting Toxicity, Death, AIDS-Defining Events, Virologic Failure and Objective Response in Step 2 | With AIDS-defining events | 1 Participants |
| ET+ART | Number of Participants With IERC-Confirmed KS Disease Progression, Dose-Limiting Toxicity, Death, AIDS-Defining Events, Virologic Failure and Objective Response in Step 2 | With dose-limiting toxicity | 0 Participants |
| ET+ART | Number of Participants With IERC-Confirmed KS Disease Progression, Dose-Limiting Toxicity, Death, AIDS-Defining Events, Virologic Failure and Objective Response in Step 2 | Died | 1 Participants |
| ET+ART | Number of Participants With IERC-Confirmed KS Disease Progression, Dose-Limiting Toxicity, Death, AIDS-Defining Events, Virologic Failure and Objective Response in Step 2 | With virologic failure | 2 Participants |
| ET+ART | Number of Participants With IERC-Confirmed KS Disease Progression, Dose-Limiting Toxicity, Death, AIDS-Defining Events, Virologic Failure and Objective Response in Step 2 | With IERC-confirmed KS progression | 1 Participants |
| ET+ART | Number of Participants With IERC-Confirmed KS Disease Progression, Dose-Limiting Toxicity, Death, AIDS-Defining Events, Virologic Failure and Objective Response in Step 2 | With objective response | 7 Participants |
| PTX+ART | Number of Participants With IERC-Confirmed KS Disease Progression, Dose-Limiting Toxicity, Death, AIDS-Defining Events, Virologic Failure and Objective Response in Step 2 | With dose-limiting toxicity | 0 Participants |
| PTX+ART | Number of Participants With IERC-Confirmed KS Disease Progression, Dose-Limiting Toxicity, Death, AIDS-Defining Events, Virologic Failure and Objective Response in Step 2 | With objective response | 0 Participants |
| PTX+ART | Number of Participants With IERC-Confirmed KS Disease Progression, Dose-Limiting Toxicity, Death, AIDS-Defining Events, Virologic Failure and Objective Response in Step 2 | With IERC-confirmed KS progression | 1 Participants |
| PTX+ART | Number of Participants With IERC-Confirmed KS Disease Progression, Dose-Limiting Toxicity, Death, AIDS-Defining Events, Virologic Failure and Objective Response in Step 2 | Died | 0 Participants |
| PTX+ART | Number of Participants With IERC-Confirmed KS Disease Progression, Dose-Limiting Toxicity, Death, AIDS-Defining Events, Virologic Failure and Objective Response in Step 2 | With AIDS-defining events | 0 Participants |
| PTX+ART | Number of Participants With IERC-Confirmed KS Disease Progression, Dose-Limiting Toxicity, Death, AIDS-Defining Events, Virologic Failure and Objective Response in Step 2 | With virologic failure | 1 Participants |
| PTX+ART | Number of Participants With IERC-Confirmed KS Disease Progression, Dose-Limiting Toxicity, Death, AIDS-Defining Events, Virologic Failure and Objective Response in Step 2 | With virologic failure | 1 Participants |
| PTX+ART | Number of Participants With IERC-Confirmed KS Disease Progression, Dose-Limiting Toxicity, Death, AIDS-Defining Events, Virologic Failure and Objective Response in Step 2 | With AIDS-defining events | 0 Participants |
| PTX+ART | Number of Participants With IERC-Confirmed KS Disease Progression, Dose-Limiting Toxicity, Death, AIDS-Defining Events, Virologic Failure and Objective Response in Step 2 | With dose-limiting toxicity | 0 Participants |
| PTX+ART | Number of Participants With IERC-Confirmed KS Disease Progression, Dose-Limiting Toxicity, Death, AIDS-Defining Events, Virologic Failure and Objective Response in Step 2 | With objective response | 5 Participants |
| PTX+ART | Number of Participants With IERC-Confirmed KS Disease Progression, Dose-Limiting Toxicity, Death, AIDS-Defining Events, Virologic Failure and Objective Response in Step 2 | Died | 5 Participants |
| PTX+ART | Number of Participants With IERC-Confirmed KS Disease Progression, Dose-Limiting Toxicity, Death, AIDS-Defining Events, Virologic Failure and Objective Response in Step 2 | With IERC-confirmed KS progression | 1 Participants |
Secondary
Number of Participants With IERC-Confirmed KS Disease Progression, Dose-Limiting Toxicity, Death, AIDS-Defining Events, Virologic Failure and Objective Response in Step 3
IERC-confirmed KS progression refers to KS disease progression confirmed by the IERC based on comparing follow-up KS response to study entry or best KS response with respect to clinical assessment of KS cutaneous lesions (count, character and marker lesion area), oral KS, visceral KS and tumor-associated edema and as described in the publications (Krown et al 1989, Cianfrocca et al 2002). AIDS-defining events refer to non-KS AIDS-defining diagnosis (WHO Stage 4 (2007), plus microsporidiosis, cyclospora gastroenteritis, Chagas disease and visceral leishmaniasis). Virologic failure is defined as two successive measurements of plasma HIV-1 RNA \>=1000 copies/mL at week 12 to week 24 or RNA \>=400 copies/mL at week 24 or later. Objective response refers to complete response or partial response as best overall KS response. Results are presented by Step 3 treatment arm.
Time frame: From Step 3 study entry to Step 3 discontinuation, up to 144 weeks
Population: All eligible participants who entered Step 3 with available data as of March 2018.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| ET+ART | Number of Participants With IERC-Confirmed KS Disease Progression, Dose-Limiting Toxicity, Death, AIDS-Defining Events, Virologic Failure and Objective Response in Step 3 | With AIDS-defining events | 5 Participants |
| ET+ART | Number of Participants With IERC-Confirmed KS Disease Progression, Dose-Limiting Toxicity, Death, AIDS-Defining Events, Virologic Failure and Objective Response in Step 3 | With objective response | 18 Participants |
| ET+ART | Number of Participants With IERC-Confirmed KS Disease Progression, Dose-Limiting Toxicity, Death, AIDS-Defining Events, Virologic Failure and Objective Response in Step 3 | With IERC-confirmed KS progression | 6 Participants |
| ET+ART | Number of Participants With IERC-Confirmed KS Disease Progression, Dose-Limiting Toxicity, Death, AIDS-Defining Events, Virologic Failure and Objective Response in Step 3 | With dose-limiting toxicity | 0 Participants |
| ET+ART | Number of Participants With IERC-Confirmed KS Disease Progression, Dose-Limiting Toxicity, Death, AIDS-Defining Events, Virologic Failure and Objective Response in Step 3 | Died | 3 Participants |
| ET+ART | Number of Participants With IERC-Confirmed KS Disease Progression, Dose-Limiting Toxicity, Death, AIDS-Defining Events, Virologic Failure and Objective Response in Step 3 | With virologic failure | 2 Participants |
| PTX+ART | Number of Participants With IERC-Confirmed KS Disease Progression, Dose-Limiting Toxicity, Death, AIDS-Defining Events, Virologic Failure and Objective Response in Step 3 | Died | 0 Participants |
| PTX+ART | Number of Participants With IERC-Confirmed KS Disease Progression, Dose-Limiting Toxicity, Death, AIDS-Defining Events, Virologic Failure and Objective Response in Step 3 | With AIDS-defining events | 0 Participants |
| PTX+ART | Number of Participants With IERC-Confirmed KS Disease Progression, Dose-Limiting Toxicity, Death, AIDS-Defining Events, Virologic Failure and Objective Response in Step 3 | With IERC-confirmed KS progression | 2 Participants |
| PTX+ART | Number of Participants With IERC-Confirmed KS Disease Progression, Dose-Limiting Toxicity, Death, AIDS-Defining Events, Virologic Failure and Objective Response in Step 3 | With dose-limiting toxicity | 0 Participants |
| PTX+ART | Number of Participants With IERC-Confirmed KS Disease Progression, Dose-Limiting Toxicity, Death, AIDS-Defining Events, Virologic Failure and Objective Response in Step 3 | With virologic failure | 2 Participants |
| PTX+ART | Number of Participants With IERC-Confirmed KS Disease Progression, Dose-Limiting Toxicity, Death, AIDS-Defining Events, Virologic Failure and Objective Response in Step 3 | With objective response | 5 Participants |
| PTX+ART | Number of Participants With IERC-Confirmed KS Disease Progression, Dose-Limiting Toxicity, Death, AIDS-Defining Events, Virologic Failure and Objective Response in Step 3 | With dose-limiting toxicity | 0 Participants |
| PTX+ART | Number of Participants With IERC-Confirmed KS Disease Progression, Dose-Limiting Toxicity, Death, AIDS-Defining Events, Virologic Failure and Objective Response in Step 3 | With IERC-confirmed KS progression | 8 Participants |
| PTX+ART | Number of Participants With IERC-Confirmed KS Disease Progression, Dose-Limiting Toxicity, Death, AIDS-Defining Events, Virologic Failure and Objective Response in Step 3 | Died | 7 Participants |
| PTX+ART | Number of Participants With IERC-Confirmed KS Disease Progression, Dose-Limiting Toxicity, Death, AIDS-Defining Events, Virologic Failure and Objective Response in Step 3 | With objective response | 29 Participants |
| PTX+ART | Number of Participants With IERC-Confirmed KS Disease Progression, Dose-Limiting Toxicity, Death, AIDS-Defining Events, Virologic Failure and Objective Response in Step 3 | With virologic failure | 1 Participants |
| PTX+ART | Number of Participants With IERC-Confirmed KS Disease Progression, Dose-Limiting Toxicity, Death, AIDS-Defining Events, Virologic Failure and Objective Response in Step 3 | With AIDS-defining events | 7 Participants |
Secondary
Number of Participants With IERC-Confirmed KS Disease Progression, Dose-Limiting Toxicity, Death, AIDS-Defining Events, Virologic Failure and Objective Response in Step 4
IERC-confirmed KS progression refers to KS disease progression confirmed by the IERC based on comparing follow-up KS response to study entry or best KS response with respect to clinical assessment of KS cutaneous lesions (count, character and marker lesion area), oral KS, visceral KS and tumor-associated edema and as described in the publications (Krown et al 1989, Cianfrocca et al 2002). AIDS-defining events refer to non-KS AIDS-defining diagnosis (WHO Stage 4 (2007), plus microsporidiosis, cyclospora gastroenteritis, Chagas disease and visceral leishmaniasis). Virologic failure is defined as two successive measurements of plasma HIV-1 RNA \>=1000 copies/mL at week 12 to week 24 or RNA \>=400 copies/mL at week 24 or later. Objective response refers to complete response or partial response as best overall KS response. Results are presented by Step 4 treatment arm.
Time frame: From Step 4 study entry to Step 4 discontinuation, up to 96 weeks
Population: All eligible participants who entered Step 4 with available data as of March 2018.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| ET+ART | Number of Participants With IERC-Confirmed KS Disease Progression, Dose-Limiting Toxicity, Death, AIDS-Defining Events, Virologic Failure and Objective Response in Step 4 | With IERC-confirmed KS progression | 2 Participants |
| ET+ART | Number of Participants With IERC-Confirmed KS Disease Progression, Dose-Limiting Toxicity, Death, AIDS-Defining Events, Virologic Failure and Objective Response in Step 4 | With dose-limiting toxicity | 0 Participants |
| ET+ART | Number of Participants With IERC-Confirmed KS Disease Progression, Dose-Limiting Toxicity, Death, AIDS-Defining Events, Virologic Failure and Objective Response in Step 4 | Died | 3 Participants |
| ET+ART | Number of Participants With IERC-Confirmed KS Disease Progression, Dose-Limiting Toxicity, Death, AIDS-Defining Events, Virologic Failure and Objective Response in Step 4 | With AIDS-defining events | 0 Participants |
| ET+ART | Number of Participants With IERC-Confirmed KS Disease Progression, Dose-Limiting Toxicity, Death, AIDS-Defining Events, Virologic Failure and Objective Response in Step 4 | With virologic failure | 1 Participants |
| ET+ART | Number of Participants With IERC-Confirmed KS Disease Progression, Dose-Limiting Toxicity, Death, AIDS-Defining Events, Virologic Failure and Objective Response in Step 4 | With objective response | 3 Participants |
| PTX+ART | Number of Participants With IERC-Confirmed KS Disease Progression, Dose-Limiting Toxicity, Death, AIDS-Defining Events, Virologic Failure and Objective Response in Step 4 | With virologic failure | 0 Participants |
| PTX+ART | Number of Participants With IERC-Confirmed KS Disease Progression, Dose-Limiting Toxicity, Death, AIDS-Defining Events, Virologic Failure and Objective Response in Step 4 | With IERC-confirmed KS progression | 3 Participants |
| PTX+ART | Number of Participants With IERC-Confirmed KS Disease Progression, Dose-Limiting Toxicity, Death, AIDS-Defining Events, Virologic Failure and Objective Response in Step 4 | With AIDS-defining events | 0 Participants |
| PTX+ART | Number of Participants With IERC-Confirmed KS Disease Progression, Dose-Limiting Toxicity, Death, AIDS-Defining Events, Virologic Failure and Objective Response in Step 4 | With dose-limiting toxicity | 0 Participants |
| PTX+ART | Number of Participants With IERC-Confirmed KS Disease Progression, Dose-Limiting Toxicity, Death, AIDS-Defining Events, Virologic Failure and Objective Response in Step 4 | With objective response | 3 Participants |
| PTX+ART | Number of Participants With IERC-Confirmed KS Disease Progression, Dose-Limiting Toxicity, Death, AIDS-Defining Events, Virologic Failure and Objective Response in Step 4 | Died | 2 Participants |
Secondary
Number of Participants With Kaposi's Sarcoma-Immune Reconstitution Inflammatory Syndrome (KS-IRIS) for BV+ART vs. PTX+ART
KS-IRIS is defined as any IERC-confirmed KS-progression that occurs within 12 weeks of ART-initiation that is associated with an increase in CD4 cell count of at least 50 cells/mm\^3 above the study entry value and/or a decrease in the HIV-1 RNA level by at least 0.5 log below the study entry value prior to or at the time of documented KS progression.
Time frame: From study entry to week 12
Population: All eligible participants who initiated study chemotherapy with available data as of March 2018.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| ET+ART | Number of Participants With Kaposi's Sarcoma-Immune Reconstitution Inflammatory Syndrome (KS-IRIS) for BV+ART vs. PTX+ART | 2 Participants |
| PTX+ART | Number of Participants With Kaposi's Sarcoma-Immune Reconstitution Inflammatory Syndrome (KS-IRIS) for BV+ART vs. PTX+ART | 0 Participants |
Secondary
Number of Participants With Kaposi's Sarcoma-Immune Reconstitution Inflammatory Syndrome (KS-IRIS) for ET+ART vs. PTX+ART
KS-IRIS is defined as any IERC-confirmed KS-progression that occurs within 12 weeks of ART-initiation that is associated with an increase in CD4 cell count of at least 50 cells/mm\^3 above the study entry value and/or a decrease in the HIV-1 RNA level by at least 0.5 log below the study entry value prior to or at the time of documented KS progression.
Time frame: From study entry to week 12
Population: All eligible participants who initiated study chemotherapy with available data as of March 2016.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| ET+ART | Number of Participants With Kaposi's Sarcoma-Immune Reconstitution Inflammatory Syndrome (KS-IRIS) for ET+ART vs. PTX+ART | 6 Participants |
| PTX+ART | Number of Participants With Kaposi's Sarcoma-Immune Reconstitution Inflammatory Syndrome (KS-IRIS) for ET+ART vs. PTX+ART | 0 Participants |
Secondary
Number of Participants With Objective Response for BV+ART vs. PTX+ART
The number of participants with objective response (complete response or partial response) as best overall KS response in Step 1. Overall KS response status (complete response, partial response, stable, disease progression) was based on comparing follow-up KS response to study entry or best KS response with respect to clinical assessment of KS cutaneous lesions (count, character and marker lesion area), oral KS, visceral KS and tumor-associated edema and as described in the publications (Krown et al 1989, Cianfrocca et al 2002).
Time frame: From study entry up to week 144
Population: All eligible participants who initiated study chemotherapy with available data as of March 2018.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| ET+ART | Number of Participants With Objective Response for BV+ART vs. PTX+ART | 80 Participants |
| PTX+ART | Number of Participants With Objective Response for BV+ART vs. PTX+ART | 91 Participants |
95% CI: [0.5, 1.3]
Secondary
Number of Participants With Objective Response for ET+ART vs. PTX+ART
The number of participants with objective response (complete response or partial response) as best overall KS response in Step 1. Overall KS response status (complete response, partial response, stable, disease progression) was based on comparing follow-up KS response to study entry or best KS response with respect to clinical assessment of KS cutaneous lesions (count, character and marker lesion area), oral KS, visceral KS and tumor-associated edema and as described in the publications (Krown et al 1989, Cianfrocca et al 2002).
Time frame: From study entry up to week 144
Population: All eligible participants who initiated study chemotherapy with available data as of March 2016.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| ET+ART | Number of Participants With Objective Response for ET+ART vs. PTX+ART | 18 Participants |
| PTX+ART | Number of Participants With Objective Response for ET+ART vs. PTX+ART | 34 Participants |
95% CI: [0.1, 0.7]
Secondary
Number of Participants With Peripheral Neuropathy (PN)
Presence of PN is defined as having all of the following results: presence of symptomatic PN, abnormal perception of vibrations, and absent or hypoactive deep tendon reflexes.
Time frame: Screening, Weeks 3, 6, 9, 12, 15, 18, 21. Assessment of PN for ET+ART was only done at screening, weeks 9 and 21.
Population: All eligible participants who initiated study chemotherapy with available data as of March 2018.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| ET+ART | Number of Participants With Peripheral Neuropathy (PN) | Week 21 | 5 Participants |
| ET+ART | Number of Participants With Peripheral Neuropathy (PN) | Week 18 | 6 Participants |
| ET+ART | Number of Participants With Peripheral Neuropathy (PN) | Week 9 | 3 Participants |
| ET+ART | Number of Participants With Peripheral Neuropathy (PN) | Week 6 | 1 Participants |
| ET+ART | Number of Participants With Peripheral Neuropathy (PN) | Week 3 | 1 Participants |
| ET+ART | Number of Participants With Peripheral Neuropathy (PN) | Week 12 | 3 Participants |
| ET+ART | Number of Participants With Peripheral Neuropathy (PN) | Screening | 7 Participants |
| ET+ART | Number of Participants With Peripheral Neuropathy (PN) | Week 15 | 2 Participants |
| PTX+ART | Number of Participants With Peripheral Neuropathy (PN) | Week 3 | 0 Participants |
| PTX+ART | Number of Participants With Peripheral Neuropathy (PN) | Week 15 | 0 Participants |
| PTX+ART | Number of Participants With Peripheral Neuropathy (PN) | Screening | 1 Participants |
| PTX+ART | Number of Participants With Peripheral Neuropathy (PN) | Week 18 | 0 Participants |
| PTX+ART | Number of Participants With Peripheral Neuropathy (PN) | Week 21 | 0 Participants |
| PTX+ART | Number of Participants With Peripheral Neuropathy (PN) | Week 6 | 0 Participants |
| PTX+ART | Number of Participants With Peripheral Neuropathy (PN) | Week 9 | 0 Participants |
| PTX+ART | Number of Participants With Peripheral Neuropathy (PN) | Week 12 | 0 Participants |
| PTX+ART | Number of Participants With Peripheral Neuropathy (PN) | Week 21 | 2 Participants |
| PTX+ART | Number of Participants With Peripheral Neuropathy (PN) | Screening | 0 Participants |
| PTX+ART | Number of Participants With Peripheral Neuropathy (PN) | Week 3 | 0 Participants |
| PTX+ART | Number of Participants With Peripheral Neuropathy (PN) | Week 6 | 2 Participants |
| PTX+ART | Number of Participants With Peripheral Neuropathy (PN) | Week 9 | 2 Participants |
| PTX+ART | Number of Participants With Peripheral Neuropathy (PN) | Week 12 | 4 Participants |
| PTX+ART | Number of Participants With Peripheral Neuropathy (PN) | Week 15 | 3 Participants |
| PTX+ART | Number of Participants With Peripheral Neuropathy (PN) | Week 18 | 1 Participants |
Secondary
Number of Participants With Symptomatic Peripheral Neuropathy (SPN)
SPN consists of three assessments: (1) pain, aching or burning in feet, legs, (2) pins and needles in feet, legs, and (3) numbness (lack of feeling) in feet, legs. SPN is graded on a severity scale from 0 (not present), 1 (mild) to 10 (severe). Presence of SPN is defined as having grade \>=1 in at least one of the three assessments.
Time frame: Screening, Weeks 3, 6, 9, 12, 15, 18, 21. Assessment of SPN for ET+ART was only done at screening, weeks 9 and 21.
Population: All eligible participants who initiated study chemotherapy with available data as of March 2018.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| ET+ART | Number of Participants With Symptomatic Peripheral Neuropathy (SPN) | Week 12 | 36 Participants |
| ET+ART | Number of Participants With Symptomatic Peripheral Neuropathy (SPN) | Screening | 76 Participants |
| ET+ART | Number of Participants With Symptomatic Peripheral Neuropathy (SPN) | Week 3 | 62 Participants |
| ET+ART | Number of Participants With Symptomatic Peripheral Neuropathy (SPN) | Week 6 | 46 Participants |
| ET+ART | Number of Participants With Symptomatic Peripheral Neuropathy (SPN) | Week 9 | 40 Participants |
| ET+ART | Number of Participants With Symptomatic Peripheral Neuropathy (SPN) | Week 15 | 26 Participants |
| ET+ART | Number of Participants With Symptomatic Peripheral Neuropathy (SPN) | Week 18 | 25 Participants |
| ET+ART | Number of Participants With Symptomatic Peripheral Neuropathy (SPN) | Week 21 | 30 Participants |
| PTX+ART | Number of Participants With Symptomatic Peripheral Neuropathy (SPN) | Week 6 | 0 Participants |
| PTX+ART | Number of Participants With Symptomatic Peripheral Neuropathy (SPN) | Week 12 | 0 Participants |
| PTX+ART | Number of Participants With Symptomatic Peripheral Neuropathy (SPN) | Week 21 | 4 Participants |
| PTX+ART | Number of Participants With Symptomatic Peripheral Neuropathy (SPN) | Week 3 | 0 Participants |
| PTX+ART | Number of Participants With Symptomatic Peripheral Neuropathy (SPN) | Week 15 | 0 Participants |
| PTX+ART | Number of Participants With Symptomatic Peripheral Neuropathy (SPN) | Week 9 | 14 Participants |
| PTX+ART | Number of Participants With Symptomatic Peripheral Neuropathy (SPN) | Screening | 24 Participants |
| PTX+ART | Number of Participants With Symptomatic Peripheral Neuropathy (SPN) | Week 18 | 0 Participants |
| PTX+ART | Number of Participants With Symptomatic Peripheral Neuropathy (SPN) | Screening | 59 Participants |
| PTX+ART | Number of Participants With Symptomatic Peripheral Neuropathy (SPN) | Week 3 | 34 Participants |
| PTX+ART | Number of Participants With Symptomatic Peripheral Neuropathy (SPN) | Week 6 | 32 Participants |
| PTX+ART | Number of Participants With Symptomatic Peripheral Neuropathy (SPN) | Week 18 | 15 Participants |
| PTX+ART | Number of Participants With Symptomatic Peripheral Neuropathy (SPN) | Week 9 | 27 Participants |
| PTX+ART | Number of Participants With Symptomatic Peripheral Neuropathy (SPN) | Week 21 | 20 Participants |
| PTX+ART | Number of Participants With Symptomatic Peripheral Neuropathy (SPN) | Week 15 | 16 Participants |
| PTX+ART | Number of Participants With Symptomatic Peripheral Neuropathy (SPN) | Week 12 | 23 Participants |
Secondary
Number of Participants With Treatment-related Toxicities and Adverse Events (AEs)
Adverse events classified by the site personnel as possibly, probably or definitely related to ART or chemotherapy.
Time frame: From study entry to week 240
Population: All eligible participants who initiated study chemotherapy with available data as of March 2018.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| ET+ART | Number of Participants With Treatment-related Toxicities and Adverse Events (AEs) | Any Signs/Symptoms | 9 Participants |
| ET+ART | Number of Participants With Treatment-related Toxicities and Adverse Events (AEs) | Any Laboratory | 27 Participants |
| ET+ART | Number of Participants With Treatment-related Toxicities and Adverse Events (AEs) | Any Laboratory, Diagnosis or Signs/Symptoms | 32 Participants |
| ET+ART | Number of Participants With Treatment-related Toxicities and Adverse Events (AEs) | Any Diagnosis | 12 Participants |
| PTX+ART | Number of Participants With Treatment-related Toxicities and Adverse Events (AEs) | Any Signs/Symptoms | 5 Participants |
| PTX+ART | Number of Participants With Treatment-related Toxicities and Adverse Events (AEs) | Any Laboratory, Diagnosis or Signs/Symptoms | 25 Participants |
| PTX+ART | Number of Participants With Treatment-related Toxicities and Adverse Events (AEs) | Any Diagnosis | 10 Participants |
| PTX+ART | Number of Participants With Treatment-related Toxicities and Adverse Events (AEs) | Any Laboratory | 25 Participants |
| PTX+ART | Number of Participants With Treatment-related Toxicities and Adverse Events (AEs) | Any Signs/Symptoms | 18 Participants |
| PTX+ART | Number of Participants With Treatment-related Toxicities and Adverse Events (AEs) | Any Laboratory, Diagnosis or Signs/Symptoms | 48 Participants |
| PTX+ART | Number of Participants With Treatment-related Toxicities and Adverse Events (AEs) | Any Laboratory | 39 Participants |
| PTX+ART | Number of Participants With Treatment-related Toxicities and Adverse Events (AEs) | Any Diagnosis | 16 Participants |
Secondary
Presence of Oral KS
Funding for oral KS objectives including data and sample collection was withdrawn during the study conduct.
Time frame: From study entry to week 240
Population: The corresponding outcome measure was withdrawn.
Secondary
Salivary KSHV
Funding for oral KS objectives including data and sample collection was withdrawn during the study conduct.
Time frame: Baseline, weeks 60, 120, 180, 240
Population: The corresponding outcome measure was withdrawn.
Secondary
Self-reported Adherence to ART Therapy
ART adherence is based on participant's recall of the number of missed ART doses for the past month. Perfect adherence is defined as having zero missed ART doses.
Time frame: At Weeks 6, 12, 18, 30 and 48
Population: All eligible participants who initiated study chemotherapy with available data as of March 2018.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| ET+ART | Self-reported Adherence to ART Therapy | Week 30 Perfect adherence | 66 Participants |
| ET+ART | Self-reported Adherence to ART Therapy | Week 18 Perfect adherence | 85 Participants |
| ET+ART | Self-reported Adherence to ART Therapy | Week 6 Perfect Adherence | 101 Participants |
| ET+ART | Self-reported Adherence to ART Therapy | Week 12 Perfect Adherence | 101 Participants |
| ET+ART | Self-reported Adherence to ART Therapy | Week 48 Perfect adherence | 13 Participants |
| PTX+ART | Self-reported Adherence to ART Therapy | Week 18 Perfect adherence | 29 Participants |
| PTX+ART | Self-reported Adherence to ART Therapy | Week 6 Perfect Adherence | 43 Participants |
| PTX+ART | Self-reported Adherence to ART Therapy | Week 12 Perfect Adherence | 36 Participants |
| PTX+ART | Self-reported Adherence to ART Therapy | Week 30 Perfect adherence | 13 Participants |
| PTX+ART | Self-reported Adherence to ART Therapy | Week 48 Perfect adherence | 0 Participants |
| PTX+ART | Self-reported Adherence to ART Therapy | Week 48 Perfect adherence | 20 Participants |
| PTX+ART | Self-reported Adherence to ART Therapy | Week 30 Perfect adherence | 85 Participants |
| PTX+ART | Self-reported Adherence to ART Therapy | Week 6 Perfect Adherence | 106 Participants |
| PTX+ART | Self-reported Adherence to ART Therapy | Week 18 Perfect adherence | 97 Participants |
| PTX+ART | Self-reported Adherence to ART Therapy | Week 12 Perfect Adherence | 103 Participants |
Secondary
Time to IERC-confirmed KS Progression or Death for BV+ART vs. PTX+ART
Time to IERC-confirmed KS progression or death was computed as the number of weeks between study entry and the earlier between date of IERC-confirmed KS progression or date of death. For participants who did not have the event, event time was censored at the week of last contact with the participant or at the participant's off study week, whichever is later.The 25-th percentile and hazard ratio are presented.
Time frame: From study entry to week 240
Population: All eligible participants who initiated study chemotherapy with available data as of March 2018.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| ET+ART | Time to IERC-confirmed KS Progression or Death for BV+ART vs. PTX+ART | 24.7 weeks |
| PTX+ART | Time to IERC-confirmed KS Progression or Death for BV+ART vs. PTX+ART | 38.6 weeks |
95% CI: [1.1, 2.2]
Secondary
Time to IERC-confirmed KS Progression or Death for ET+ART vs. PTX+ART
Time to IERC-confirmed KS progression or death was computed as the number of weeks between study entry and the earlier between date of IERC-confirmed KS progression or date of death. For participants who did not have the event, event time was censored at the week of last contact with the participant or the participant's off study week, whichever is later. The 25-th percentile and hazard ratio are presented.
Time frame: From study entry to week 240
Population: All eligible participants who initiated study chemotherapy with available data as of March 2016.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| ET+ART | Time to IERC-confirmed KS Progression or Death for ET+ART vs. PTX+ART | 17.9 weeks |
| PTX+ART | Time to IERC-confirmed KS Progression or Death for ET+ART vs. PTX+ART | 30.0 weeks |
95% CI: [1.1, 3.4]
Other Pre-specified
Cellular and Humoral Markers of Immune Function and Activation
The protocol did not distinguish between outcome measures essential to the primary publication and those of lesser importance and priority which are not the focus of the study but intended for subsequent publications of exploratory analyses, conditional on primary results and additional funding. This outcome measure was listed under secondary outcome measures in the study protocol but was intended for an exploratory analysis to evaluate the relationship between response of KS to therapy and development of KS-IRIS with cellular and humoral markers of immune function and activation. The laboratory assays for this outcome measure have not been completed.
Time frame: Baseline, weeks 60, 120, 180, 240
Other Pre-specified
Immunohistochemical Evaluations of Viral and Cellular Gene Expression
The protocol did not distinguish between outcome measures essential to the primary publication and those of lesser importance and priority which are not the focus of the study but intended for subsequent publications of exploratory analyses, conditional on primary results and additional funding. This outcome measure was listed under secondary outcome measures in the study protocol but was intended for an exploratory analysis to evaluate the relationship between response of KS to therapy and development of KS-IRIS with immunohistochemical markers of viral and cellular gene expression in KS tumors. The laboratory assays for this outcome measure have not been completed.
Time frame: Baseline, 24-48 hours after 2nd chemo-therapy cycle begins
Other Pre-specified
Peripheral Blood Mononuclear Cell (PBMC) KSHV
The protocol did not distinguish between outcome measures essential to the primary publication and those of lesser importance and priority which are not the focus of the study but intended for subsequent publications of exploratory analyses, conditional on primary results and additional funding. This outcome measure was listed under secondary outcome measures in the study protocol but was intended for an exploratory analysis to investigate the relationship between plasma and PBMC KSHV viral load. The laboratory assays for this outcome measure have not been completed.
Time frame: Baseline, weeks 60, 120, 180, 240
Other Pre-specified
Plasma KS-associated Herpesvirus (KSHV)
The protocol did not distinguish between outcome measures essential to the primary publication and those of lesser importance and priority which are not the focus of the study but intended for subsequent publications of exploratory analyses, conditional on primary results and additional funding. This outcome measure was listed under secondary outcome measures in the study protocol but was intended for an exploratory analysis to investigate the relationship between plasma and PBMC KSHV viral load. The laboratory assays for this outcome measure have not been completed.
Time frame: Baseline, weeks 60, 120, 180, 240
Other Pre-specified
Quality of Life Measures
The protocol did not distinguish between outcome measures essential to the primary publication and those of lesser importance and priority which are not the focus of the study but intended for subsequent publications of exploratory analyses, conditional on primary results and additional funding. This outcome measure was listed under secondary outcome measures in the study protocol but was intended for an exploratory analysis to compare measures of quality of life in ET+ART, BV+ART and PTX+ART.
Time frame: Baseline, weeks 60, 120, 180, 240
Other Pre-specified
RNA Levels for KSHV Genes
The protocol did not distinguish between outcome measures essential to the primary publication and those of lesser importance and priority which are not the focus of the study but intended for subsequent publications of exploratory analyses, conditional on primary results and additional funding. This outcome measure was listed under secondary outcome measures in the study protocol but was intended for an exploratory analysis to evaluate the relationship between response of KS to therapy and development of KS-IRIS with RNA levels for KSHV genes in tumor biopsies. The laboratory assays for this outcome measure have not been completed.
Time frame: Baseline, weeks 60, 120, 180, 240